Role of Ivermectin and Colchicine in Treatment of COVID-19: A Randomized Controlled Clinical Trial
DOI:
https://doi.org/10.51699/ijbea.v3i1.3296Keywords:
Ivermectin, Colchicine, COVID-19, Clinical Trial, Ain Shams UniversityAbstract
Objective: To assess the effectiveness of ivermectin and colchicine as treatment options for COVID-19. Patients and methods: A three-arm randomized controlled clinical trial was conducted in triage clinic of family medicine department at Ain Shams University Hospitals on participants who had been diagnosed as COVID-19 patients with moderate severity. Patients aged <18 years or >65 years with any co-morbidities, pregnant or lactating female and with mild or severe COVID-19 confirmed cases were excluded. Randomization was done by using sealed envelopes for intervention or control. Patients are followed up to improvement of patient’s symptoms with no development of new symptoms over one month. Results: A total of 120 patients with COVID-19 were enrolled in the study, 40 patients in each arm. Their mean age was 40.16(SD 10.74) years. Out of them, 44 (36.6%) were male, 76(63.4%) were female. Mean duration of symptoms was 9.58 (SD 2.206), 9.9 (SD 2.07), and 9.53 (SD 2.37) in the ivermectin, colchicine and control groups, respectively. Most patients (67.5%, 70% and 72.5%) cured with residual symptoms with no difference in between the ivermectin, colchicine and control groups, respectively (P>0.05). Conclusion: Ivermectin and colchicine have no beneficial effect over the standard care in treatment of COVID-19.
References
Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China—key questions for impact assessment. N Engl J Med. 2020 ;382:692-4.
Worldometer. COVID-19 CORONAVIRUS Pandemic. Available at: https://www.worldometers.info/coronavirus (Last access May 24, 2021).
Van Norman GA. Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs. JACC Basic TranslSci. 2016;1(3):170-9.
Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6(1):1-8.
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.
Kaur H, Shekhar N, Sharma S, Sarma P, Prakash A, Medhi B. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep. 2021;73(3):736-49.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
Laing R, Gillan V, Devaney E. Ivermectin—old drug, new tricks? Trends Parasitol. 2017;33:463-72.
Karatza E, Ismailos G, Karalis V. Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens. Xenobiotica. 2021;51(6):643-56.
Schlesinger N, Firestein BL, Brunetti L. Colchicine in COVID-19: an old drug, new use. CurrPharmacol Rep. 2020;6(4):137-45.
Hellwig MD, Maia A. A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin. Int J Antimicrob Agents. 2021;57(1):106248
Gómez-Hernández MT, Novoa NM, Antúnez P, Jiménez MF.Ivermectin treatment may improve the prognosis of patients with COVID-19. ArchBronconeumol. 2020;56(12):816-30.
Sandhu T, Tieng A, Chilimuri S, Franchin G. A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection. Can J Infect Dis Med Microbiol. 2020;2020:8865954.
Teranaka W, Pan D. Discharge criteria for patients with COVID-19 to long-term care facilities requires modification. Clin Med (Lond). 2021;21(1):e116-7.
Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrob Agents. 2021;57(1):106239.
Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403.
Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of ChloroquineDiphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(4):e208857-e.
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al.Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020;383(21):2041-52.
Bukhari KHS, Asghar A, Perveen N, Hayat A, Mangat SA, Butt KR, et al. Efficacy of ivermectin in COVID-19 patients with mild to moderate disease. medRxiv 2021. Available at: https://www.medrxiv.org/content/10.1101/2021.02.02.21250840v1
Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214-6.
Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double-blind, dose-response study in Lagos. QJM. 2022;114(11):780-8.
Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021;32:100720.
Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial. EClinicalMedicine. 2021;37:100959.
Ravikirti Roy R, Pattadar C, Raj R, Agarwal N, Biswas B, et al. Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in eastern India. J Pharm PharmSci. 2021;24:343-50.
Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC Infect Dis. 2021;21:635.
Mohan A, Tiwari P, Suri T. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial. PREPRINT (Version 1) 2021. Research Square; 2021. DOI: 10.21203/rs.3.rs-191648/v1
Abd-Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES, Soliman S, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study. J Med Virol. 2021;93:5833-8.
Podder CS, Chowdhury N, Sina MI, Haque WMMU. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. IMC J Med Sci. 2021;14:11-8.
Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. BiotechnolBiotechnol Equip. 2020;34(1):469-74.
Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. Am J Trop Med Hyg. 2020;102(6):1156-7.
Tardif JC, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021;9:924-32.
Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Paño-Pardo JR, Power NR, Sibani M, Szabo BG, Tsiodras S. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clinical Microbiology and Infection .2022;28(2):222-38.
Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical Trial. JAMA Netw Open. 2020;3.
Lopes M.I., Bonjorno L.P., Giannini M.C., Amaral N.B., Menezes P.I., Dib S.M., et al. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021;7(1):e001455.
Mehta KG, Patel T, Chavda PD, Patel P. Efficacy and safety of colchicine in COVID-19: A meta-analysis of randomised controlled trials. RMD Open. 2021;7(3):e001746.
Sanghavi D, Bansal P, Kaur IP, Mughal MS, Keshavamurthy C, Cusick A, Schram J, Yarrarapu SN, Giri AR, Kaur N, Moreno Franco P. Impact of colchicine on mortality and morbidity in COVID-19: a systematic review. Annals of Medicine. 2022;54(1):775-89.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
